Rapamune Off-Label Suit Prompts Congressional Investigation
This article was originally published in The Pink Sheet Daily
Executive Summary
House Oversight Committee is investigating allegations Wyeth promoted Rapamune for unapproved uses. Chairman Towns says he is concerned the drug was targeted to high-risk African-Americans; Pfizer says the drug is not contraindicated for this population.